SMAD3 and idiopathic pulmonary fibrosis: We found no significant difference in binding levels of Smad3 to the ITGB6 promoter between IPF (n = 10) and non-fibrotic control (n = 9) donors, although one IPF donor did demonstrate markedly increased Smad3 binding above all other donors (Fig 6F).